Embed Size (px)
Citation preview
1
STANDING OPERATING
PROCEDURES (SOPs)
FOR
PUBLIC HEALTH DEPARTMENT
GOVERNMENT OF MAHARASHTRA
2
Content
Sr.No Chapters Page Nos.
1 Introduction 3-8
2 Standing Operating Procedures (SOPs)
9-13
3 Standard Precautions 14-21
4 Communication & Reporting Plans 22-26
5 Annexures 27-33
3
Chapter 1
INTRODUCTION
4
Chapter 1
INTRODUCTION
Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, and
often fatal illness in humans. EVD has a case fatality rate of up to 90%. EVD outbreaks
have occurred in Liberia, Nigeria, Sierra Leon, Guinea and Congo in West Africa in the
past few days and are seen to spread rapidly.
Genus Ebola virus is 1 of 3 members of the Filoviridae family (filovirus) along with
genus Marburgvirus and genus Cuevavirus. Genus Ebolavirus comprises 5 distinct
species:
1. Bundibugyo ebolavirus (BDBV)
2. Zaire ebolavirus (EBOV)
3. Reston ebolavirus (RESTV)
4. Sudan ebolavirus (SUDV)
5. Taï Forest ebolavirus (TAFV).
Fruit bats of the Pteropodidae family are considered to be the natural host of the Ebola
virus. The virus is transmitted to people from wild animals and spreads in the human
population through human-to-human transmission with infection resulting from direct
contact (through broken skin or mucous membranes) with the blood, secretions, organs
or other body fluids of infected people, and indirect contact with environment
contaminated with such fluids.
Health-care workers have frequently been infected while treating patients with
suspected or confirmed EVD. This has occurred through close contact with patients
when infection control precautions are not strictly practiced.
EVD is a severe acute viral illness often characterized by the sudden onset of fever,
intense weakness, muscle pain, headache and sore throat. This is followed by vomiting,
5
diarrhea, rash, impaired kidney and liver function, and in some cases, both internal and
external bleeding.
Laboratory findings include low white blood cell and platelet counts and elevated liver
enzymes. People are infectious as long as their blood and secretions contain the virus.
The incubation period, that is, the time interval from infection with the virus to onset of
symptoms, is 2 to 21 days.
Ebola virus infections can be diagnosed definitively in a laboratory through several types
of tests:
Antibody-capture enzyme-linked immunosorbent assay (ELISA)
Antigen detection tests
Serum neutralization test
Reverse transcriptase polymerase chain reaction (RT-PCR) assay
Electron microscopy
Virus isolation by cell culture.
No licensed vaccine for EVD is available. No specific treatment is available.
New drug therapies are being evaluated.
CASE DEFINITIONS
Clinical case definitions
(i) Suspected case :- Patient having history of travel or close contact with
symptomatic person traveling from Ebola Virus Disease affected areas in the past 21
days, with high grade fever more than 101 degrees F, along with one or more of the
following additional symptoms:-
Headache
Body ache
Unexplained haemorrhage
Abdominal pain
6
Diarrhoea
Vomiting
(ii) Confirmed case: A case with the above features and laboratory confirmed
diagnostic evidence of Ebola virus infection at a BSL-3 facility by any one of the
following:-
Ig M (ELISA)
Antigen detection
RT-PCR
Treatment
1. Currently, no specific therapy is available that has demonstrated efficacy
in the treatment of EVD. In the absence of specific therapy, a number of
modalities have been tried/ experimented. None of them have been
scientifically validated.
2. General medical support is critical. Such care must be administered with
strict attention to barrier isolation. All body fluids (blood, saliva, urine, and
stool) contain infectious virions and should be handled with great care.
3. Steroid therapy has no role.
4. There is no role for antibiotics unless there is evidence of secondary bacterial
infection
Supportive Care
1. Supportive therapy with attention to intravascular volume, electrolytes, nutrition, and
comfort care is of benefit to the patient. Intravascular volume repletion is one of the
most important supportive measures.
2. For high grade fever patient should be treated with only tablet Paracetamol. No
other analgesic, antipyretic and in particular aspirin should be given in this
case as these drugs may increase chances of bleeding. Tepid sponging should
be done repeatedly to bring down the temperature immediately in case of high grade
fever.
7
3. Due to repeated vomiting and diarrhea, patient may suffer from shock and electrolyte
imbalance. Without vomiting and diarrhea, patient also may have shock due to capillary
leakage and haemo-concentration may be observed in this case. Plenty of oral fluid may
be advised in mild hypotensive cases or those who have no vomiting and diarrhea.
4. There may be transient bone marrow suppression and patient may suffer from
leucopenia and thrombocytopenia for which patient may develop bleeding at different
sites and may have also superadded infection. Patient should be transfused with
platelets when the count is below 20000/cumm or bleeding from any sites irrespective
of platelet count.
5. In case of severe shock and vomiting patient may be treated with intravenous fluid
with crystalloid or colloid. Intravenous fluid therapy should be carefully monitored to
avoid fluid overload as most of the deaths are associated with it due to rapid correction
of fluid in severe shock. Blood transfusion may be required in some cases those who
have severe gastrointestinal bleeding and shock. Management should include
replacement of coagulation factors and heparin if disseminated intravascular
coagulation develops.
6. Patient may present with different organ involvement commonly liver and kidney.
Patient may suffer from jaundice due to liver impairment and acute renal failure due to
acute tubular necrosis in case of profound shock or direct renal involvement by Ebola
virus. Patient may require dialysis in severe case of renal failure.
7. Patient may require ICU support for breathlessness due to lung involvement or
critical condition.
9. Isolation ICUs will have to be established to sequester the patient.
10. High morbidity and mortality is associated with different co-morbid illness,
therefore EVD patients should be carefully treated with known case of Hypertension,
Diabetes, coronary artery diseases and pregnancy. Patients those who are on Anti-
platelet drugs should be temporarily stopped as these drugs may increase chance of
bleeding.
10. Co-infection with EVD should be immediately treated with proper antibiotic. In the
early stage, if co-infection is not treated properly patient may develop sepsis and septic
shock which may lead to fatal outcome.
8
Diet and Activity
Nutrition becomes complicated due to nausea, vomiting, and diarrhea. Good hydration
is to be ensured with adequate protein supplement.
EXPERIMENTAL THERAPY: ZMAPP and TKM-Ebola
ZMapp drug is being developed by Mapp Biopharmaceutical Inc., a result of the
collaboration between Mapp Biopharmaceutical, LeafBio, Defyrus Inc.(Toronto), the
U.S. government and the Public Health Agency of Canada. The antibody work came out
of research projects funded by the U.S. Army more than a decade ago and years of
funding by the Public Health Agency of Canada. The FDA has allowed two drugs, ZMapp
and an RNA interference drug called "TKM-Ebola", to be used in people infected with
Ebola under these programs.
In light of the 2014 Ebola Outbreak, an expert panel from the World Health
Organization (WHO) announced on August 12, 2014, "In the particular circumstances of
this outbreak, and provided certain conditions are met, the panel reached consensus
that it is ethical to offer unproven interventions with as yet unknown efficacy and
adverse effects, as potential treatment or prevention". Supplies of both ZMapp and
TKM-Ebola are limited. And there are various other obstacles, such as regulatory
ones, to be surmounted before the drugs can be used.
9
Chapter 2
STANDARD OPERATING
PROCEDURES (SOPs) FOR
AIRPORT & SEAPORT
10
Chapter 2
STANDARD OPERATING PROCEDURES (SOPs)
FOR AIRPORT
1. At Entry Level
1. Screening of passengers from international flights and categorization
of passengers according to risks at Mumbai, Pune and Nagpur Airports
as:-
a. Low Risk
b. Medium Risk
c. High Risk
2. At Mumbai Airport, passengers will be screened by Airport Health
Officer (APHO) and at Pune and Nagpur by Medical teams deployed by
Deputy Directors of Health Services of the region. (Annexure 3)
3. List of medium risk passengers communicated to Municipal
Corporation of Greater Mumbai (MCGM) when the passenger is from
Mumbai Corporation area & Integrated Dieses Surveillance Project,
Maharashtra, when the passenger is from rest of Maharashtra.
(Annexure 1)
4. 30 days follow-up is carried out telephonically or actively by MCGM for
all listed passengers from Mumbai corporation area
5. 30 days follow-up is carried out telephonically or directly by staff visit
by IDSP Maharashtra or civil surgeons of districts where the
passenger is residing for passengers from rest of the Maharashtra
excluding Mumbai
11
2. At Referral Level
During screening, if any High Risk Passengers is identified or during 30
days follow up, any of the medium risk passenger develops symptoms
suggestive of Ebola, the suspect will be shifted by designated ambulances
(Annexure 4) either to :
1. Isolation facility at Jogeshwari Trauma Centre, if the patient is from
MCGM area.
2. Isolation facility of Naidu Hospital in Pune and Govt. Medical
College in Nagpur when the suspect is from rest of Maharashtra.
3. At Isolation Level
1. Person isolated & treatment given symptomatically at isolation
facility(Annexure 5)
2. Immediately Blood Sample send to NIV
3. If the result comes negative, passengers will be discharged according
to medical condition
4. If the result of blood sample comes positive, patient will be treated for
Ebola at the same facility for rest of Maharashtra (i.e. in Naidu
Hospital Pune and Government Medical College Nagpur) according to
guidelines for the management of Ebola patient.
5. If the result of blood sample comes positive, patient shifted to
Kasturba Hospital for further management in Mumbai.
6. Also, all the positive pregnant women and seriously ill positive patients
from MCGM will be shifted to JJ Hospital for further management in
Mumbai.
12
STANDARD OPERATING PROCEDURES (SOPs) FOR SEAPORT
1.At entry level
1. Screening of passengers from Sea Ports and categorization of
passengers according to risks by port health officers :
a. Low Risk
b. Medium Risk
c. High Risk
2. At Mumbai port trust (MPT), Jawaharlal Nehru port trust (JNPT) and
the five minor ports in the area of MCGM (annexure 6) and at the other
minor ports in rest of Maharashtra after screening of passengers list of
medium risk passengers communicated to Municipal Corporation of
Greater Mumbai (MCGM) & Integrated Dieses Surveillance Project,
Maharashtra.
3. 30 days follow-up is carried out telephonically by MCGM for all listed
passengers from Mumbai corporation area.
4. 30 days follow-up is carried out telephonically or directly by staff visit
by IDSP Maharashtra or civil surgeons of districts where the passenger
is residing for passengers from rest of the Maharashtra.
13
2.At Referral level
During screening if any High Risk Passengers is identified or during 30
days follow up any of the medium risk passenger develops symptoms
suggestive of Ebola, the suspect will be shifted by designated ambulances
either to :
1. Isolation facility at Jogeshwari Trauma Centre if the patient is from
MCGM area.
2. Isolation facility of District Hospital in Alibaug, Ratnagiri & Oras
when the suspect is from rest of Maharashtra.
3. At Isolation level
1. Person isolated & treatment given symptomatically
2. Immediately Blood Sample Send to NIV
3. If the result comes negative passengers will be discharged according to
medical condition
4. If the result of blood sample comes positive patient will be treated for
Ebola at the same facility for rest of Maharashtra ( i.e. in the district
hospitals of Alibaug, Ratnagiri and Oras ) according to guidelines for
the management of Ebola patient.
5. If the result of blood sample comes positive patient shifted to Kasturba
Hospital for further management in Mumbai.
6. Also all the positive pregnant women and seriously ill positive patients
from MCGM will be shifted to JJ Hospital for further management in
Mumbai.
14
Chapter 3
STANDARD PRECAUTIONS
15
Chapter 3 STANDARD PRECAUTIONS
1. Hand hygiene
Clean your hands by rubbing them with an alcohol based formulation (20–30 sec), as
the preferred mean for routine hygienic hand antisepsis if hands are not visibly soiled. It
is faster, more effective, and better tolerated by your hands than washing with soap and
water.
Wash your hands with soap and water (40–60 sec) when hands are visibly dirty or
visibly soiled with blood or other body fluids or after using the toilet.
Indications:
1. Before touching a patient: Clean your hands before touching a patient when
approaching him/her
2. Before clean / aseptic procedure: Clean your hands immediately before accessing a
critical site with infectious risk for the patient (e.g. a mucous membrane, non-intact
skin, an invasive medical device)
3. After body fluid exposure risk: Clean your hands as soon as the task involving an
exposure risk to body fluids has ended (and after glove removal)
4. After touching a patient: Clean your hands when leaving the patient’s side after
having touched the patient
5. After touching patient surroundings: Clean your hands after touching any object or
furniture when living the patient surroundings, without having touched the patient
2. Gloves
Wear GLOVES when touching blood, body fluids, secretions, excretions, mucous
membranes, non intact skin. Change GLOVES between tasks and procedures on the
same patient after contact with potentially infectious material. Remove THEM after use,
before touching non-contaminate items and surfaces, and before going to another
patient.Perform hand hygiene immediately after removal.
16
3. Facial protection (eyes, nose, and mouth)
Wear a surgical or procedure mask and eye protection (eye visor, goggles) or a face
shield to protect mucous membranes of the eyes, nose, and mouth during activities that
are likely to generate splashes or sprays of blood, body fluids, secretions, and excretions.
4. Gown
Wear to protect skin and prevent soiling of clothing during activities that are likely to
generate splashes or sprays of blood, body fluids, secretions, or excretions. Remove
soiled gown as soon as possible, and perform hand hygiene.
5. Prevention of needle stick and injuries from other sharp instruments
Use care when: Handling needles, scalpels, and other sharp instruments or devices.
6. Respiratory hygiene and cough etiquettes
Persons with respiratory symptoms should apply source control measures: Cover their
nose and mouth when coughing/sneezing with tissue or mask, dispose of used tissues
and masks, and perform hand hygiene after contact with respiratory secretions.
Health-care facilities should: Place acute febrile respiratory symptomatic patients at
least 1 metre (3 feet) away from others in common waiting areas, if possible. Post visual
alerts at the entrance to health-care facilities instructing persons with respiratory
symptoms to practice respiratory hygiene/cough etiquette. Consider making hand
hygiene resources, tissues and masks available in common areas and areas used for the
evaluation of patients with respiratory illnesses.
7. Environmental cleaning
Use adequate procedures for the routine cleaning and disinfection of environmental and
other frequently touched surfaces.
17
8. Linens
Handle, transport, and process used linen in a manner which: Prevents skin and
mucous membrane exposures and contamination of clothing.
Avoids transfer of pathogens to other patients and or the environment.
9. Waste disposal
Ensure safe waste management. Treat waste contaminated with blood, body fluids,
secretions and excretions as clinical waste, in accordance with local regulations. Human
tissues and laboratory waste that is directly associated with specimen processing should
also be treated as clinical waste. Discard single use items properly.
10. Patient care equipment
Handle equipment soiled with blood, body fluids, secretions, and excretions in a manner
that prevents skin and mucous membrane exposures, contamination of clothing, and
transfer of pathogens to other patients or the environment. Clean, disinfect, and
reprocess reusable equipment appropriately before use with another patient. Cleaning
used instruments. Disposal of used needles and other sharp instruments.
Direct Patient Care (For suspected or confirmed patient)
PATIENT PLACEMENT, STAFF ALLOCATION, VISITORS
Put suspected or confirmed cases in single isolation rooms with an adjoining dedicated
toilet or latrine, showers, sink equipped with running water, soap and single-use towels,
alcohol-based hand rub dispensers, stocks of personal protective equipment (PPE),
stocks of medicines, good ventilation, screened windows, doors closed and restricted
access; if isolation rooms are unavailable, cohort these patients in specific confined
areas while rigorously keeping suspected and confirmed cases separate and ensure the
items listed here for isolation rooms are readily available. Make sure that there is at
least 1 meter (3 feet) distance between patient beds.
18
Restrict all non-essential staff from HF patient care areas. Stopping visitor access to the
patient is preferred, but if this is not possible, limit their number to include only those
necessary for the patient’s well-being and care, such as a child’s parent. Do not allow
other visitors to enter the isolation rooms/areas and ensure that any visitors wishing to
observe the patient do so from an adequate distance (approximately 15 m or 50 feet).
Before allowing visitors to HF patients to enter the HCF, screen them for signs and
symptoms of HF.
(a) Isolate the patient
(b) Follow standard precautions including appropriate Personal Protective Equipment
(PPE)
(c) Restrict visitors
(d) Avoid aerosol generating procedures.
(e) Implement environmental infection control measures.
(f) Proper disposal of potentially infected material following biohazard precautions.
Ensure that clinical and non-clinical personnel are assigned exclusively to HF
patient care areas and that members of staff do not move freely between the
HF isolation areas and other clinical areas during the outbreak
19
Operational guidelines for Isolation Ward
Component Recommendations Comments
Patient Placement Single patient room (containing a private bathroom) with the door closed.
To maintain a log of all persons entering the patient's room
To ensure appropriate and consistent use of PPE by all persons entering the patient room
Personal Protective Equipment (PPE)
All persons entering the patient room should wear at least: o Additional PPE might be required in certain situations (e.g., copious amounts of blood, other body fluids, vomit, or feces present in the environment), including but not limited to: o Double gloving o Disposable shoe covers
Leg coverings
o PPE should be worn by all Health Care Provider upon entry into patient rooms or care areas. Ensure that PPE should be carefully removed & discarded as per hospital waste Management guidelines. The person handling waste should wear full PPE. o Hand hygiene should be performed before donning PPE & immediately after removal of PPE
Patient Care Equipment
Dedicated medical equipment (preferably disposable, when possible) should be used for the provision of patient care
All non-dedicated, non-disposable medical equipment used for patient care should be cleaned and disinfected according to manufacturer's instructions
The Equipment should be as far as possible dedicated to isolation rooms.
Patient Care Considerations
Limit the use of needles and other sharp objects as much as possible.
Limit the use of phlebotomy and laboratory testing to the
minimum necessary for essential diagnostic evaluation and patient care.
If the use of sharp objects cannot be avoided, ensure to follow safe injection practices.
All needles and sharps should be handled with extreme care and disposed in puncture-proof, sealed containers & follow as per hospitals guidelines for disposal.
Aerosol Generating Procedures on patients
To be avoided as far as possible.
If unavoidable follow a procedure to minimize exposures from aerosol-generating procedures when performed on Ebola HF patients.
Visitors /relatives should not be
Because of the potential risk to individuals reprocessing reusable respirators, disposable filtering face piece respirators & equipment should be preferred.
Define a list of procedures
20
Component Recommendations Comments
present.
Limit the number of health care providers present during the procedure for the activity.
Conduct the procedures in a Isolation Room as far as possible. Room doors should be kept closed during the procedure except when entering or leaving the room, and entry and exit should be minimized during and shortly after the procedure.
HCP should wear complete PPE with N95 masks during the procedure.
Disinfect the room after the procedure is over.
If re-usable equipment is used, they should be cleaned and disinfected according to manufacturer instructions and hospital policies.
Collection and handling of soiled re-usable respirators must be done by trained individuals using PPE as described above for routine patient care
like intubation, etc.
Environmental Infection Control
Environmental cleaning and disinfection and safe handling of potentially contaminated materials is paramount, as blood, sweat, emesis, feces and other body secretions represent potentially infectious materials
o health care providers performing environmental cleaning and disinfection should carry out all activities after wearing complete set of PPE & follow hospital infection control guidelines strictly.
Ebola virus is susceptible to all commonly used disinfectants e.g sodium hypochlorite (1%)
Duration of Infection Control Precautions
Till the patient is in hospital & as the patient is infectious even after he /she is asymptomatic hence even at home safety precautions to be followed till
It will help in containment.
21
Component Recommendations Comments
two months from the date of onset of the symptoms appeared
Self health monitoring
Recommended for all health care providers and visitors & contacts. For a period of 21 days of last exposure.
Supports spread of disease & containment there off.
Isolation Room with Lobby
Sssss
Staff door Bed door
WC
Lobby
Window Window
22
Chapter 4
Communication and Reporting Plans
23
Communication and Reporting Plan for Mumbai Airport
Serious cases and pregnant
woman sent to JJ Hospital
Screening at Mumbai Airport
by APHO / Medical Teams
Low risk passengers
Allow to leave with
30 days passive
surveillance
Medium Risk
Passengers
Inform MCGM if the
passenger is from
Mumbai Corporation
Area (Dr. Gomare)
Inform IDSP
Maharashtra if the
passenger is from rest
of Maharashtra
(Dr. Jagtap)
High Risk
Passengers
Telephonic / Active
follow up for 30 days
Information
passed on to
designated
Ambulance and
transfer by
Ambulance
Transfer to
Jogeshwari
Facility
Inform
Jogeshwari
facility in
transit
Inform NIV and
sent sample
If found +ve, inform
to Jogeshwari
Hospital and sent to
Kasturba Hospital
If found +ve,
inform to
IDSP
Maharashtra
Daily Reporting by IDSP
Maharashtra to :
1.IDSP GOI
2. Chief Secretary, Govt.
of Maharashtra
3. Principal Secretary,
PHD Maharashtra
4. Director Health
Services, Mumbai
24
Communication and Reporting Plan for Nagpur and Pune Airport
Screening at Nagpur & Pune
Airport by Medical Teams
Low risk passengers
Allow to leave with
30 days passive
surveillance
Medium Risk
Passengers
Inform Dy. Director
Health Services
Nagpur & Pune
Inform IDSP
Maharashtra if the
passenger is from rest
of Maharashtra
(Dr. Jagtap)
High Risk
Passengers
Telephonic / Active
follow up for 30 days
Information passed
on to designated
Ambulance and
transfer by
Ambulance
Transfer to Naidu
Hospital (Pune),
Govt. Medical
College, Nagpur
Inform
isolation
facility in
transit
Inform NIV and
sent sample
If found +ve start treatment
according to Management
Guidelines provided by State
If found +ve,
inform to
IDSP
Maharashtra
Daily Reporting by IDSP
Maharashtra to :
1.IDSP GOI
2. Chief Secretary Govt.
of Maharashtra
3. Principal Secretary
PHD Maharashtra
4. Director Health
Services Mumbai
25
Communication and Reporting Plan for Mumbai Port Trust, Jawaharlal Nehru Port Trust & Five
Small Ports under MCGM
Serious cases and pregnant
woman sent to JJ Hospital
Screening at Port Health Officer
(PHO) / Medical Teams
Low risk passengers
Allow to leave with
30 days passive
surveillance
Medium Risk
Passengers
Inform MCGM if the
passenger is from
Mumbai
Corporation Area (Dr. Gomare)
Inform IDSP
Maharashtra if the
passenger is from rest
of Maharashtra (Dr. Jagtap)
High Risk
Passengers
Telephonic / Active
follow up for 30 days Information passed
on to designated
Ambulance and
transfer by
Ambulance
Transfer to
Jogeshwari
Facility
Inform
Jogeshwari
facility in
transit
Inform NIV and
sent sample
If found +ve, inform
to Jogeshwari
Hospital and sent to
Kasturba Hospital
If found +ve,
inform to
IDSP
Maharashtra
Daily Reporting
(Annexure 7) by IDSP
Maharashtra to :
1.IDSP GOI
2. Chief Secretary Govt. of
Maharashtra
3. Principal Secretary
PHD Maharashtra
4. Director Health
Services Mumbai
26
Communication and Reporting Plan for
Seven Small Ports in rest of Maharashtra
Screening at Ports by
Medical Teams
Low risk passengers
Allow to leave with
30 days passive
surveillance
Medium Risk
Passengers
Inform Dy. Director
Health Services
Thane & Kolhapur
Inform IDSP
Maharashtra if the
passenger is from rest
of Maharashtra
(Dr. Jagtap)
High Risk
Passengers
Telephonic / Active
follow up for 30 days
Information passed
on to designated
Ambulance and
transfer by
Ambulance
Transfer to district
hospitals of Alibaug,
Ratnagiri & Oras
depending on location
of port
Inform
isolation
facility in
transit
Inform NIV and
sent sample
If found +ve start treatment
according to Management
Guidelines provided by
State
If found +ve,
inform to
IDSP
Maharashtra
Daily Reporting by IDSP
Maharashtra to:
1.IDSP GOI
2. Chief Secretary Govt.
of Maharashtra
3. Principal Secretary
PHD Maharashtra
4. Director Health
Services Mumbai
27
Chapter 5
ANNEXURES
28
Annexure 1
Information of Control Rooms
No. Name Phone Fax email
1 State Control Room Pune
020 – 26 12 57 92 020 – 26 12 95 74
jdhsh@rediffmail
.com
2 Regional Control room Pune Circle
020 – 26 12 68 70
020 – 26 13 51 36
ddhspune@rediffmai
l.com
3 Regional Control room Nagpur Circle
0712 – 2461933 0712 – 2465988
ddhsngp@rediffmail.
com
4 Control room MCGM Mumbai
022 – 23054897
022 – 23020855
epidcellmcgm@gmail
.com
Annexure 2
List of Nodal Officers of various Departments for EVD Preparedness
Sr.No Department Name of Officer /Email ID Mobile No.
1 Public Health Department
Mumbai
Dr.Sham Nimgade
9623438530
022-22634475/
22703785
2 Jt. Director of Health
Services (MF &W)Pune
Dr.Kanchan Jagtap
9922114981
020-26125792
3 IDSP, Maharashtra Dr.Pradip Awate
9423337556
020-26129574
4 Directorate of Medical
Education Research,
Mumbai
Dr.S.P.Rao
9422193852
022-22620361-65
5 Mumbai Corporation &
Greater Mumbai (MCGM)
Dr.Mangala Gomare
9833898688 022 – 23054897
29
Sr.No Department Name of Officer /Email ID Mobile No.
6 NIV, Pune Dr.Yogesh Gurav
9822318278 020-
26006390
7 Airport Health Officer
Mumbai APHO
Dr.Shivdikar
9969135263
8 Port Health Officer MPT Dr.Sule
9869036627
9 Port Health Officer JNPT Dr.P.M.Gaikwad
9867587968
10 Chief Port Officer Mumbai
Maritime Board
Comdt.Arun Saxena
9967338366
Annexure 3
Medical teams at Airport
Airport Team members Timing Day of operation
Attending
Mumbai
Dr.Shivdikar 24 Hours
All Days
International flights from Ebola Affected countries and middle east countries
Dr.Raman
Nagpur
Dr.Kalode 4.40 am
Wed, Fri, Sun
Airlines Arabia Dr.Mohammad
Dr. Mate Dr.Khobragade
Pune
Dr.Kante 2 pm to 5 pm
Tue, Thur, Sun
Air India, Dubai
Dr.Murkute 3 am to 7.30 am
Mon, Wed, Thurs, Sat
Lufthansa LH768 Frankfrut
3 am to 7.30 am
Tue, Wed, Fri, Sun
Spicejet S-052 Sharjah
30
Annexure 4
EMS Ambulance for transport
Sr
No District Vehicle No Doctors Name Mobile No
1
MUMBAI
MH14 CL 1410
Dr.Kanchan Virendra Bobade 7875771355
Dr.Vaseem Ahmd Zaheer --
2 MUMBAI MH14 CL 1253 Dr.Nisha Dayaram Rangari 7875771387
Dr.Dhairyashil Jayawant
Magar --
3
NAGPUR
MH14 CL 0510
Dr.Roshni Gajbhiye 7774081952
Dr.Anrup Basod --
Dr.Mamta Shirbate --
4
PUNE
MH14 CL 1136
Dr.Anand Kharat 8378957062
Dr.Maksud Mujawar --
Annexure 5
Isolation wards
Sr
No Name of the Hospital
Name of Nodal
Officer Mobile No. & Email ID Beds
1 Jogeshwari Trauma
Center, Mumbai
Dr. Shashikant
Wadekar, MS
Ph- 9833082373
E-mail- [email protected] 10
2 Kasturba Hospital,
Mumbai
Dr. Chandrakant
Pawar
Ph- 9869246651
E-mail-
10
3 J J Hospital, Mumbai Dr.Nitin Bavdekar 9004115538
4 Naidu Hospital , Pune Dr. Fancis Benedict. 9689931858 /
5 G.M.C Nagpur Dr Hedaoo Medical
Superintendent
9822929137
31
Annexure 6
*List of Small Ports near Mumbai
Sr.
No
Name of Port Designated Isolation
facility
Veh.Reg
.No
EMSO
Mobile
Number
EA Mobile
Number
1 MSPNP Maritime Services Ltd. A-
5,Ionic, 18 Arthur Bunder road.
Colaba, Mumbai Ph. 22884537
Trauma Center Jogeshwari
(BMC)
Dr.S.Wadekar 98330822373
MH 14
CL 1403
7875771387 7757061934
2 M/sDighi Port Ltd New Excelsior
Bldg, 6th Floor, A.K.Nayak Marg,
Fort Mumbai Ph. 22074824
Trauma Center Jogeshwari
(BMC)
Dr.S.Wadekar 98330822373
MH 14
CL 1403
7875771387 7757061934
3 M/sReliance Infrastructure Ltd
Dahanu Thermal Power Station,
Dahanu Road, thane Ph 02528-
225000
Trauma Center Jogeshwari
(BMC)
Dr.S.Wadekar 98330822373
MH 14
CL 0869
8378957195 8275999775
4 M/s Ashapura Minechem Ltd
Jeevan Udyog Bldg. 3rd flr, 278
D.N.Road,Fort, Mumbai
Trauma Center Jogeshwari
(BMC)
Dr.S.Wadekar 98330822373
MH 14
CL 1403
7875771387 7757061934
5 M/s Indo Energy International
ltd, 610, Vindya Comm. Complex,
Sector 11 CBD Belapur, Navi
Mumbai Ph. 27580578
Trauma Center Jogeshwari
(BMC)
Dr.S.Wadekar 98330822373
MH 14
CL 1268
8378957057 7768044881
#List of 7 Other Small Ports
Sr.
No
Name of Port Designated Isolation
facility
Veh.Re
g.No
EMSO
Mobile
Number
EA Mobile
Number
1 M/SsJSW Ispat industries
Spong Iron Unit Geetapurum
Dolvi Tal Pen, Dist Raigad
District Hospital Alibaug
Ph.No. 02341-222157 .
MH 14
CL 0609
8378957214 8275999714
2 M/s Welspun Maxsteel Ltd
village salav, P.O.Revdanda
Dist Raigad ph.02144-260110
District Hospital Alibaug
Ph.No. 02341-222157 .
MH 14
CL 1116
7774085913 8275999361
3 Chouwgule Ports &
Infrastructure Ltd. (Agre Port)
Sande Lavgan PO Jaiagad Ph
District Hospital
Ratnagiri
Ph.No. 02352-222106 .
MH 14
CL 0987
7774085956 8275999539
32
Sr.
No
Name of Port Designated Isolation
facility
Veh.Re
g.No
EMSO
Mobile
Number
EA Mobile
Number
02357-242491 02352-222363
4 M/sRatnagiri Gas & Power
pvt.ltd At & Post – Anjalwel
Tal Guhagar Dist Ratnagiri
ph.02359-241350
District Hospital
Ratnagiri
Ph.No. 02352-222106 .
02352-222363
MH 14
CL 0991
7774085993 8275999580
5 Phinolex Industries ltd
Ranpar-Pawas Road P.O.Box
No.11 Ratnagiri Ph.02352-
238027
District Hospital
Ratnagiri
Ph.No. 02352-222106 .
02352-222363
MH 14
CL
0608
7709001908 8275999570
6 M/s JSWJaighar Port Ltd PO
Jaigarh, Tal &Dist Ratnagiri
Ph.02357-242551
District Hospital
Ratnagiri
Ph.No. 02352-222106 .
02352-222363
MH 14
CL 0987
7774085956 8275999539
7 M/s.Redi Port Ltd. Redi Port,
Redi Village, Tal-Vengurlla,
Redi ph.02366-268590
District Hospital Oros
Ph.No. 02362-228900 .
02352-228654
MH 14
CL 1120
7774085957 8275999537
33
Annexure 7
Format used for daily reporting – Ebola Viral Disease (EBVD)- Daily Update – Maharashtra State
Date
A] Suspected Patient information
Place
No of persons with Ebola like illness
under hospital isolation
No of samples sent to NIV
No of samples positive
for Ebola
Confirmed cases No of Deaths
O P O P O P O P O P
Mumbai
Pune
A’bad
Nagpur
Total
B] Screening Information
Place
No of Passengers from affected
countries reported by EMR
No of Passengers
Transported from airport
No of Passengers
traced telephonically
/ physically
* Out of …….. passengers, 30 days follow up of ……
passengers has been completed.
O P O P O P
Mumbai
Pune
Nagpur
Rest of MAH
Total
C] Material Supply –
Particulars
Balance available with
State as on 1 Aug 2014
Received from GOI/
Procured
Total Availabl
e Issued
Balance as on today
PPE O - On Day… / P - Progressive
D] Other Information Related to Ebola Prevention & Control –
(Important information about Meetings, Trainings, Workshops, Media Briefs & other Ebola related activities)
34
Public Health Department
Government of Maharashtra
Mantralaya, Mumbai
